Specifically, E2F3 was enriched in eight pathways spanning transcription initiation, cell cycle regulation (G2 phase, G1/S-related processes, and fat cell proliferation), apoptosis modulation, and cancer pathways, including pancreatic, breast, and bladder cancer, as well as cellular senescence, underscoring its central role in proliferation-related chemotherapy sensitivity. This evidence concerns the gene E2F3 and urinary bladder cancer.